Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?
Faecal short-chain fatty acids - a diagnostic biomarker for irritable bowel syndrome?
复制标题
DOI：
10.1186/s12876-016-0446-z
复制
发表时间：
2016-04-27
影响因子：
2.4
通讯作者：
Hestad K
中科院分区：
文献类型：
--
作者：
Farup PG;Rudi K;Hestad K
肠易激综合征（IBS）的诊断依赖于基于ESTA的标准。一个有效和可靠的生物标志物，可以确认诊断是可取的。本研究评估了粪便短链脂肪酸（SCFA）作为IBS诊断生物标志物的特性。25例IBS受试者和25例对照者被纳入本解释性病例对照研究。用气相色谱法分析粪便样品的SCFA（乙酸、丙酸、丁酸、异丁酸、戊酸和异戊酸），并报告为mmol/l和摩尔%。在寻找区分患有和不患有IBS的受试者的最佳方法时，测量了SCFA的总量和每种SCFA的量，并计算了SCFA之间的比例和差异。在IBS组和对照组中，平均年龄分别为46.2（SD 12.9）和49.2（SD 14.6），女性人数分别为13/25（52%）和15/25（60%）。丙酸和丁酸之间的差异（mmol/l）具有最佳的诊断特性，受试者工作特征曲线下的面积为0.89（95%CI：0.80-0.98）（p < 0.001）。以0.015 mmol/l为界值，诊断IBS的敏感性、特异性、阳性和阴性似然比和诊断优势比分别为92%、72%、3.29、0.11和29.6。所有IBS亚组显示出相似的诊断特性。该研究表明，粪便SCFA可能是区分健康受试者与IBS受试者的非侵入性、有效和可靠的生物标志物。
The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based criteria. A valid and reliable biomarker that could confirm the diagnosis is desirable. This study evaluated the properties of faecal short-chain fatty acids (SCFA) as diagnostic biomarkers for IBS. Twenty-five subjects with IBS and 25 controls were included in this explanatory case–control study. Stool samples were analysed for SCFA (acetic acid, propionic acid, butyric acid, isobutyric acid, valeric acid, and isovaleric acid) with gas chromatography and reported as mmol/l and molar%. In the search for the best way to distinguish between subjects with and without IBS, the total amount and the amount of each of the SCFA were measured, and the proportions and differences between the SCFA were calculated. In the IBS and control group, the mean age was 46.2 (SD 12.9) and 49.2 (SD 14.6), and the number of females was 13/25 (52 %) and 15/25 (60 %) respectively. The difference between propionic and butyric acid (mmol/l) had the best diagnostic properties, the area under the Receiver Operating Characteristic curve was 0.89 (95 % CI: 0.80–0.98) (p < 0.001). With a cut-off value > 0.015 mmol/l indicating IBS, the sensitivity, specificity, positive and negative likelihood ratio, and diagnostic odds ratio were 92 %, 72 %, 3.29, 0.11 and 29.6 respectively. Similar diagnostic properties were shown for all the IBS subgroups. The study indicated that faecal SCFA could be a non-invasive, valid and reliable biomarker for the differentiation of healthy subjects from subjects with IBS.